EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production

Dianji Tu, Cheng Lu, Junfeng Guo, Qiao Chen, Xin Li, Yingjie Wang, Lulu Cheng, Hongfei Jiang, Jincheng Jian, Yusong Ge, Zhanjie Hou, Xiaojie Feng und 10 weitere

Clinical and Molecular Hepatology · 01.01.2026 · 32 (1) · 221-238

DOI: 10.3350/cmh.2025.0577 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.01.2026. Verfasst von Dianji Tu und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Xinqiao Hospital, Army Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Berberine, Gastrointestinal Microbiome, Serotonin, Cholestasis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Cholestatic liver disease (CLD) is a pathological condition characterized by impaired bile formation, secretion, and excretion. However, the key pathophysiological mechanisms of CLD remain elusive, and therapeutic efficacy is unsatisfactory.

Methods

We administered berberine (BBR) or dihydroberberine (dhBBR) in bile duct ligation-, ANIT-, and mdr2-/- CLD mouse models to evaluate the anti-CLD effect. We conducted fecal microbiota transplantation to determine the role of gut microbiota in BBR’s effect. We conducted a randomized, controlled clinical trial to evaluate the effects of BBR in patients with CLD.

Results

Oral BBR alleviates cholestatic liver injury in multiple mouse models. Gut microbes can transform BBR into dhBBR, which suppresses 5-hydroxytryptamine (5-HT) production in gut enterochromaffin cells by antagonizing tryptophan hydroxylase 1 (TPH1) activity and downregulating Tph1 transcription. This further ameliorates CLD by interrupting the 5-HT/5-HTR axis. A clinical study validated that BBR improved blood biochemical indicators in patients with CLD and decreased 5-HT levels.

Conclusions

BBR is transformed by gut microbiota to ameliorate CLD via inhibiting 5-HT, suggesting potential novel strategies for further clinical use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BerberineGastrointestinal MicrobiomeSerotoninCholestasisAnimalsHumansMiceMaleDisease Models, AnimalTryptophan HydroxylaseFemaleMice, Inbred C57BLMiddle AgedFecal Microbiota TransplantationLiver

Stichwörter der Autor:innen

5-HTBerberineCholestatic liver diseaseDihydroberberineGut microbiota

Substanzen

BerberineSerotoninTryptophan Hydroxylase

Autor:innen und Institutionen

  • Department of Gastroenterology, Xinqiao Hospital, Army Medical University, Chongqing, China.
  • 3National Drug Clinical Trial Institution, Xinqiao Hospital, Army Medical University, Chongqing, China.
  • Chongqing Institute for Brain and Intelligence, Guangyang Bay Laboratory, Chongqing, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Tu, D., Lu, C., Guo, J., Chen, Q., Li, X., Wang, Y., Cheng, L., Jiang, H., Jian, J., Ge, Y., Hou, Z., Feng, X., Feng, Y., Zhou, J., Lei, Y., Diao, H., Ran, L., Zhou, Y., Xu, Z., …, & Yang, S. (2026). Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production. Clinical and Molecular Hepatology, 32(1), 221-238. https://doi.org/10.3350/cmh.2025.0577

Vancouver

Tu D, Lu C, Guo J, Chen Q, Li X, Wang Y, et al. Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production. Clinical and Molecular Hepatology. 2026;32(1):221-238. doi:10.3350/cmh.2025.0577

BibTeX
@article{Tu2026,
  author = {Tu, Dianji and Lu, Cheng and Guo, Junfeng and Chen, Qiao and Li, Xin and Wang, Yingjie and Cheng, Lulu and Jiang, Hongfei and Jian, Jincheng and Ge, Yusong and Hou, Zhanjie and Feng, Xiaojie and Feng, Yunxuan and Zhou, Jianchun and Lei, Yuanyuan and Diao, Hua and Ran, Lei and Zhou, Yuanyuan and Xu, Zhengguo and Zhou, Jiyin and Tang, Bo and Yang, Shiming},
  title = {Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  volume = {32},
  number = {1},
  pages = {221--238},
  doi = {10.3350/cmh.2025.0577}
}
Kostenlos starten →